Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 6/2015

01-12-2015 | Original Article

Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status

Authors: Yoshihiro Nishida, Satoshi Tsukushi, Hiroshi Urakawa, Shunsuke Hamada, Eiji Kozawa, Kunihiro Ikuta, Yuichi Ando, Naoki Ishiguro

Published in: International Journal of Clinical Oncology | Issue 6/2015

Login to get access

Abstract

Background

This study was conducted to determine the efficacy and safety of low-dose chemotherapy with methotrexate (MTX) and vinblastine (VBL) for patients with desmoid tumors refractory to meloxicam treatment, focusing in particular on the relationship between the efficacy of this chemotherapy and catenin β-1 (CTNNB1) mutation status.

Patients and methods

Since March 2003, patients pathologically diagnosed with extraperitoneal desmoid tumors have been prospectively treated with meloxicam, a COX-2 inhibitor, at our institution. Patients with inoperable tumors who were resistant to meloxicam treatment underwent MTX and VBL therapy every other week. The responses of all patients were evaluated, and factors that were correlated with efficacy were analyzed, including CTNNB1 mutation status.

Results

Sixty-eight patients were prospectively treated with meloxicam. MTX + VBL therapy was administered in 15 patients. Six patients showed a partial response. Only one patient presented disease progression. A few patients showed grade 3–4 treatment-related toxicity with the administration of MTX and VBL every other week. Intriguingly, CTNNB1 status did not affect the efficacy of this treatment.

Conclusion

MTX and VBL treatment every other week is well tolerated and achieved a favorable response in patients resistant to meloxicam treatment, regardless of CTNNB1 mutation status.
Literature
1.
2.
Ballo MT, Zagars GK, Pollack A et al (1999) Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 17(1):158–167PubMed
3.
Gronchi A, Casali PG, Mariani L et al (2003) Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 21(7):1390–1397CrossRefPubMed
4.
Huang K, Fu H, Shi YQ et al (2009) Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution. J Surg Oncol 100(7):563–569CrossRefPubMed
5.
Lev D, Kotilingam D, Wei C et al (2007) Optimizing treatment of desmoid tumors. J Clin Oncol 25(13):1785–1791CrossRefPubMed
6.
Merchant NB, Lewis JJ, Woodruff JM et al (1999) Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer 86(10):2045–2052CrossRefPubMed
7.
Nuyttens JJ, Rust PF, Thomas CR Jr et al (2000) Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer 88(7):1517–1523CrossRefPubMed
8.
Salas S, Dufresne A, Bui B et al (2011) Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 29(26):3553–3558CrossRefPubMed
9.
Shido Y, Nishida Y, Nakashima H et al (2009) Surgical treatment for local control of extremity and trunk desmoid tumors. Arch Orthop Traum Surg 129(7):929–933CrossRef
10.
Colombo C, Miceli R, Lazar AJ et al (2013) CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer 119(20):3696–3702CrossRefPubMed
11.
Lazar AJ, Tuvin D, Hajibashi S et al (2008) Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 173(5):1518–1527PubMedCentralCrossRefPubMed
12.
van Broekhoven DL, Verhoef C, Grunhagen DJ et al (2015) Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol 22(5):1464–1470CrossRefPubMed
13.
Briand S, Barbier O, Biau D et al (2014) Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. J Bone Joint Surg Am 96(8):631–638CrossRefPubMed
14.
Gronchi A, Colombo C, Le Pechoux C et al (2014) Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French Sarcoma Group. Ann Oncol 25(3):578–583PubMedCentralCrossRefPubMed
15.
Nishida Y, Tsukushi S, Shido Y et al (2010) Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study. J Clin Oncol 28(6):e107–e109CrossRefPubMed
16.
Skapek SX, Anderson JR, Hill DA et al (2013) Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children’s Oncology Group (COG) phase II study. Pediatr Blood Cancer 60(7):1108–1112PubMedCentralCrossRefPubMed
17.
de Camargo VP, Keohan ML, D’Adamo DR et al (2010) Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 116(9):2258–2265PubMedCentralPubMed
18.
Gega M, Yanagi H, Yoshikawa R et al (2006) Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 24(1):102–105CrossRefPubMed
19.
Poon R, Smits R, Li C et al (2001) Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene 20(4):451–460CrossRefPubMed
20.
Hamada S, Urakawa H, Kozawa E et al (2014) Nuclear expression of beta-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoid tumors. Tumour Biol 35(5):4561–4566CrossRefPubMed
21.
Azzarelli A, Gronchi A, Bertulli R et al (2001) Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 92(5):1259–1264CrossRefPubMed
22.
Lackner H, Urban C, Kerbl R (1997) Noncytotoxic drug therapy in children with unresectable desmoid tumors. Cancer 80(2):334–340CrossRefPubMed
23.
Hamada S, Futamura N, Ikuta K et al (2014) CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study. PLoS One 9(5):e96391PubMedCentralCrossRefPubMed
24.
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247CrossRefPubMed
25.
Skapek SX, Ferguson WS, Granowetter L et al (2007) Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol 25(5):501–506CrossRefPubMed
26.
Meazza C, Bisogno G, Gronchi A et al (2010) Aggressive fibromatosis in children and adolescents: the Italian experience. Cancer 116(1):233–240PubMed
27.
Garbay D, Le Cesne A, Penel N et al (2012) Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol 23(1):182–186CrossRefPubMed
28.
Domont J, Salas S, Lacroix L et al (2010) High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer 102(6):1032–1036PubMedCentralCrossRefPubMed
29.
Chugh R, Wathen JK, Patel SR et al (2010) Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 16(19):4884–4891CrossRefPubMed
30.
Heinrich MC, McArthur GA, Demetri GD et al (2006) Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 24(7):1195–1203CrossRefPubMed
31.
Penel N, Le Cesne A, Bui BN et al (2011) Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 22(2):452–457CrossRefPubMed
32.
33.
Jo JC, Hong YS, Kim KP et al (2014) A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. Investig New Drugs 32(2):369–376CrossRef
34.
Bonvalot S, Eldweny H, Haddad V et al (2008) Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 34(4):462–468CrossRefPubMed
Metadata
Title
Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status
Authors
Yoshihiro Nishida
Satoshi Tsukushi
Hiroshi Urakawa
Shunsuke Hamada
Eiji Kozawa
Kunihiro Ikuta
Yuichi Ando
Naoki Ishiguro
Publication date
01-12-2015
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 6/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0829-0

Other articles of this Issue 6/2015

International Journal of Clinical Oncology 6/2015 Go to the issue

Original Article

The efficacy of radio-frequency ablation for metastatic lung or liver tumors of male germ cell tumors as an alternative minimally invasive therapy after salvage chemotherapy

Original Article

Clinical characteristics and outcome of pneumothorax after stereotactic body radiotherapy for lung tumors

Original Article

Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations

Original Article

Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer

Original Article

Efficacy of intraoperative entire-circumferential frozen section analysis of lumpectomy margins during breast-conserving surgery for breast cancer

Original Article

Clinical outcomes of weekly cisplatin chemoradiotherapy for patients with pyriform sinus cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits